Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Crizotinib (Xalkori®)

Status: Available in 2019 for NF2 in the United States and Canada

Crizotinib - Chemical Structure
Trade Name: Xalkori™
Chemical Compound: Crizotinib
Synonyms: CRZ, PF-2341066, PF-02341066,
PF2341066, PF-2341066, PF 2341066
Pharmaceutical Company: Pfizer
Legal Status: ℞ - Prescription
Administered By: Pill - Oral
Tumor Target: Schwannoma
Protein Target: FAK1 (PTK2) Inhibitor
NF2 Trials: Recruiting Trial: NCT02465060
IUPAC/Chemical Name: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-
Formula: C21H22Cl2FN5O

Helpful Facts

  • In trials for: Breast Cancer, solid tumor cancer
  • Solubility: Soluble in DMSO, not in water. Dimethyl Sulfoxide (DMSO) is an organosulfur compound with the formula (CH3)2SO.
  • Mammalian target of rapamycin (mTOR) serine/threonine kinase (dual mTOR Complex 1 and 2 inhibitor, mTORC1 and mTORC2)
  • Inhibitor: inhibits the membrane receptor MET and activation of the MET signaling pathway

Side Effects

  • fatigue
  • nausea
  • mucositis
  • rash
  • constipation
  • vomiting
  • dyspnea
  • cough


  1. Zhao, Yingchao, et al. "Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models." Proceedings of the National Academy of Sciences (2018): 201719966.
    Source: http://www.pnas.org/content/early/2018/02/07/1719966115 | DOI: 10.1073/pnas.1719966115

  2. Troutman, Scott, et al. "Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1." Oncotarget 7.34 (2016): 54515.
    Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342359/ | DOI: 10.18632/oncotarget.10248

  3. National Center for Biotechnology Information. PubChem Compound Database; "CID=11626560", (accessed Jan. 12, 2018) Source: https://pubchem.ncbi.nlm.nih.gov/compound/11626560

  4. MedKoo Biosciences. "Crizotinib - MedKoo CAT#: 202222" (accessed Jan. 12, 2018) Source: http://www.medkoo.com/products/4537
  5. U.S. Food and Drug Administration. "FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer." (March 11, 2016)
    Source: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm490329.htm